PSY30 IMPACT OF PSORIASIS INTEGRATED CLINIC (CLIPSO) STAFF IN ELIMINATE WASTEFUL SPENDING IN HEALTHCARE, MEDELLIN – COLOMBIA

Abstract

describe the economic impact generated CLIPSO's staff by adequate prescription and switching treatment of psoriasis. a retrospective observational cross-sectional study in patients with moderate-severe psoriasis evaluated by CLIPSO's staff from May-2018 to December-2019. The staff is an interdisciplinary group formed by dermatologists, rheumatologists, internist physicians, pharmacists, nurses, physical therapists, nutritionists, and psychologists, which periodically meets to define in a consensus the most appropriate therapy for each patient. The patients evaluated were referred to the staff by an external or CLIPSO's dermatologists to the initiation or switching their treatment. We define an economic impact when the patients arrived with the expectation of beginning a biologic therapy and the staff defines begin with non-biologic systemic therapy or topical therapy. For the descriptive analysis of qualitative variables, relative and absolute frequencies were used, and quantitative variable summary measures (central tendency, scatter, position). A normality test was performed. The proportion of patients who do not switch their therapy and the savings generated by staff were calculated. R Core Team statistical package (2019) was used. during the study, the active population was 1007 patients, of which, 380/1007 (37.7%) were analyzed by staff. Of these, 74/380 patients (19.5%) arrived the expectation with biologic therapy spectating, but began with non-biologic systemic therapy alone or combination with topical therapy. Metotrexate (37.5%), Daivobet (29.7%), Acitretin (17.2%), Chemophototherapy (4.7%), Metotrexate+Daivobet (3.1%), Clobetasol (3.1%), Cyclosporine (1.6%) or Azathioprine (1.6%). 39/74 (52.7%) had a time of 12 months or more after the intervention (average 16±2.2 months) without beginning biologic therapy and with successful therapeutic, generating a total saving of 711.570 USD [1]. CLIPSO's staff generated an impact on eliminating wasteful spending by biologic therapy use in psoriasis.